Biotech & Life Sciences

  • Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology

    Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology

    Astellas Pharma and Vir Biotechnology just announced a global strategic collaboration. The deal centers on VIR-5500, an investigational T-cell engager (TCE) for prostate cancer. I’m looking at the financial terms—it’s a massive commitment. Vir is receiving $335 million upfront with a total deal value potentially hitting $1.7 billion. I see a clear signal here: the…

    read more

  • Johnson & Johnson Reports Long‑Term TREMFYA Data: 80% in Remission

    Johnson & Johnson Reports Long‑Term TREMFYA Data: 80% in Remission

    Johnson & Johnson (NYSE:JNJ) has announced new long‑term data from the QUASAR LTE study, showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. More than 80% of patients were in clinical remission, over 50% achieved endoscopic remission, and nearly 79% showed histo‑endoscopic…

    read more

  • Vanda Wins FDA Nod for BYSANTI, a New Antipsychotic Tablet

    Vanda Wins FDA Nod for BYSANTI, a New Antipsychotic Tablet

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has announced FDA approval of BYSANTI™ (milsaperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity in the atypical antipsychotic class, offering patients and providers a novel therapeutic option with a…

    read more

  • Brookdale Raises Liquidity to $377.7M After Refinancing $550M of Debt

    Brookdale Raises Liquidity to $377.7M After Refinancing $550M of Debt

    Brookdale Senior Living Inc. (NYSE:BKD) announced results for the quarter and the year ending 2025, consistent with preliminary figures shared in January. The company highlighted stronger occupancy, improved revenue per available unit, and progress on refinancing and portfolio optimization. Fourth quarter highlights Same community results showed resident fees up 5.0 percent, with occupancy climbing 250…

    read more

  • Retevmo Delivers Clinically Meaningful Event‑Free Survival in Phase 3 Trial

    Retevmo Delivers Clinically Meaningful Event‑Free Survival in Phase 3 Trial

    Eli Lilly and Company (NYSE:LLY) announced positive topline results from its Phase 3 LIBRETTO‑432 trial, evaluating Retevmo (selpercatinib) as adjuvant therapy in patients with early‑stage RET fusion‑positive non‑small cell lung cancer (NSCLC). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in event‑free survival compared to placebo. Trial highlights Overall…

    read more

  • Hands‑Free AI Reading Now Live in U.S. Radiology Practices

    Hands‑Free AI Reading Now Live in U.S. Radiology Practices

    Coreline Soft has partnered with INFINITT North America to embed its AVIEW AI platform directly into the INFINITT PACS environment. The result is a fully automated, zero‑click AI reading solution now live in U.S. radiology practices. Radiologists can access AI‑powered insights without extra logins or workflow interruptions, making advanced technology part of everyday clinical practice.…

    read more

  • St. Luke’s Rolls Out Secure Cloud Imaging Archive With Sectra

    St. Luke’s Rolls Out Secure Cloud Imaging Archive With Sectra

    St. Luke’s University Health Network has rolled out a new enterprise imaging solution from Sectra. Instead of juggling different systems, all images now flow into one secure archive. Radiology, cardiology, ophthalmology, and other specialties feed into the same platform, making it easier for caregivers to pull up studies instantly no matter where they were created.…

    read more

  • FDA Clears ArkBio to Begin U.S. Trial of Anti‑Fibrotic AK3280

    FDA Clears ArkBio to Begin U.S. Trial of Anti‑Fibrotic AK3280

    Strategic Clinical Milestone Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept clinical trial in the United States, marking a…

    read more

  • Deloitte Research Highlights Growing Divide in Health Care AI Adoption

    Deloitte Research Highlights Growing Divide in Health Care AI Adoption

    Deloitte LLP has released new research showing a growing divide in health care between early adopters of agentic AI and more cautious organizations. The report indicates that 85% of health care leaders plan to increase investment in agentic AI over the next two to three years, with 61% already building or implementing initiatives. Adoption Challenges…

    read more

  • Hospital Adoption Targeted With Sky Labs’ CART ON Ring Device

    Hospital Adoption Targeted With Sky Labs’ CART ON Ring Device

    Sky Labs has launched CART ON, a hospital ward solution that uses a ring-type wearable to continuously measure and manage inpatient blood pressure. The release marks the company’s expansion from outpatient and consumer monitoring into inpatient care, targeting one of the most workflow-intensive areas of hospital operations. For investors and healthcare operators, the move signals…

    read more